Here’s what you may have missed in the world of Boston tech.
Namogoo, a company whose technology protects e-commerce websites against malware, is doubling its Boston team within the next year, thanks to a fresh $15 million Series B round.
The company hopes to treat autoimmune diseases and allergies by engineering regulatory T cells.
Carl Murphy brings more than a decade of experience managing sales teams in healthcare and other critical industries.
This is an extension of a Series A Sayata initially announced in August, bringing the round’s total to $52 million.
The oversubscribed Series C will help HDAI expand into health systems across the country.
We're always looking for news.
